Psychedelic Research and Access in
South Korea
Blossom currently tracks 6 psychedelic clinical trials connected to South Korea, including 1 active study. The country page also links to 2 stakeholders, giving the page ecosystem context beyond registered studies.
Data updated
Key Insights
A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inSouth Korea.
- 1
Blossom tracks 6 psychedelic clinical trials connected to South Korea, including 1 active study.
- 2
Visible trial compounds include Esketamine.
- 3
Visible trial topics include Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD).
- 4
The country page links to 2 stakeholders in Blossom's ecosystem data.
- 5
The country access guide currently classifies access as "Medical Only (Private)"; details vary by compound and care setting.
Research and Access Snapshot
Blossom currently tracks 6 psychedelic clinical trials connected to South Korea, including 1 active study.
- Active trials
- 1
- Total trials
- 6
- Stakeholders
- 2
- Events
- 0
Currently active studies
Linked to this country
Linked organisations
No linked events
Top Compounds
- Esketamine(6)
Top Study Topics
- Treatment-Resistant Depression (TRD)(4)
- Major Depressive Disorder (MDD)(2)
Active Trial Preview
View all trials →Medical Access
South Korea maintains a restrictive legal regime for classical psychedelics: most serotonergic/hallucinogenic compounds (psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, ayahuasca/DMT-containing plants, mescaline, 2C-X) are controlled under the national Narcotics Control Act and have no authorized medical use outside approved research. Esketamine is an exception - it received domestic marketing authorization and is available through regulated medical settings, while racemic/other ketamine formulations remain legal for approved medical uses (anesthesia...
Regulatory Status
The linked medical access and reimbursement guide summarises South Korea as "Medical Only (Private)". South Korea maintains a restrictive legal regime for classical psychedelics: most serotonergic/hallucinogenic compounds (psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, ayahuasca/DMT-containing plants, mescaline, 2C-X) are controlled under the national Narcotics Control Act and have no authorized medical use outside approved research. Esketamine is an exception - it received domestic marketing authorization and is available through regulated medical settings, while racemic/other ketamine formulations remain legal for approved medical uses (anesthesia, analgesia) and are used off-label in private psychiatric practice for depression but generally without routine public.
Country Details
- Region
- Asia
- Last updated
- 4 May 2026
Country Report
Medical Only (Private)Medical Access
South Korea maintains a restrictive legal regime for classical psychedelics: most serotonergic/hallucinogenic compounds (psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, ayahuasca/DMT-containing plants, mescaline, 2C-X) are controlled under the national Narcotics Control Act and have no authorized...
Open access guide →Pro Scorecard
Country Scorecard
Compare evidence, access, payment, delivery, local ecosystem, and review confidence for South Korea.
Open scorecard →Psychedelic Stakeholders in South Korea
Organisations, sponsors, clinics, and research groups connected to psychedelic science in South Korea.
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in South Korea.